{"gene":"GABRA3","run_date":"2026-06-09T23:54:44","timeline":{"discoveries":[{"year":2016,"finding":"GABRA3 activates the AKT pathway to promote breast cancer cell migration, invasion, and metastasis. A-to-I RNA-edited GABRA3 has reduced cell surface expression and suppresses AKT activation required for cell migration and invasion, thereby suppressing metastasis.","method":"Loss-of-function and gain-of-function cell-based assays (migration, invasion), AKT pathway activation assays, cell surface expression analysis of edited vs. unedited GABRA3","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal functional assays (KD and OE), AKT pathway readout, cell surface localization, replicated across multiple cancer models in single rigorous study","pmids":["26869349"],"is_preprint":false},{"year":2017,"finding":"miR-92b-3p directly targets GABRA3 (confirmed by dual-luciferase reporter assay), and miR-92b-3p overexpression suppresses GABRA3 expression, leading to inactivation of AKT/mTOR and JNK oncogenic pathways in pancreatic cancer cells.","method":"Dual-luciferase reporter assay, qPCR, immunoblotting, in vitro migration/invasion assays, xenograft mouse models","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase reporter validates direct targeting, pathway readouts, single lab with multiple orthogonal methods","pmids":["29078789"],"is_preprint":false},{"year":2017,"finding":"Rare missense variants in the extracellular GABA-binding NH2-terminus, M2-M3 linker, and M4 transmembrane segment of GABRA3 cause a variable but significant reduction of GABA-evoked anion currents compared to wild-type, indicating loss-of-function as the pathomechanism for associated epilepsy and intellectual disability.","method":"Functional electrophysiology in Xenopus laevis oocytes expressing mutant vs. wild-type GABRA3; X-chromosome inactivation studies; fibroblast expression analysis for microduplication variant","journal":"Brain : a journal of neurology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct electrophysiological reconstitution in Xenopus oocytes for multiple variants with defined domain localizations, multiple families studied","pmids":["29053855"],"is_preprint":false},{"year":2016,"finding":"GABRA3 induces MMP-2 and MMP-9 expression through activation of the JNK/AP-1 signaling pathway, enhancing lymphatic metastasis in lung adenocarcinoma both in vitro and in vivo.","method":"In vitro invasion assays, in vivo mouse models, pathway activation analysis (JNK/AP-1), MMP expression measurement after GABRA3 modulation","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo functional assays with defined pathway readout, single lab","pmids":["27081042"],"is_preprint":false},{"year":2020,"finding":"Edited GABRA3 (A-to-I; I343M) has higher transcript and protein stability compared to unedited GABRA3 in glioma cells. Exogenously expressed edited GABRA3 inhibits migration and invasion of glioma cells more efficiently than unedited GABRA3, demonstrating that RNA editing stabilizes GABRA3 protein and suppresses the invasive phenotype.","method":"Exogenous expression of edited vs. unedited GABRA3 in glioma cells, transcript and protein level quantification, migration and invasion assays","journal":"PeerJ","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct comparison of edited vs. unedited protein with functional migration/invasion readout, single lab","pmids":["33062411"],"is_preprint":false},{"year":2010,"finding":"GABRA3 regulates behavioral despair (immobility in Tail Suspension Test) in vivo; pharmacological positive modulation of the GABRA3-encoded alpha3 subunit with SB-205384 significantly reduced TST immobility in wild-type mice but had no effect in NZB mice lacking hippocampal Gabra3 expression.","method":"QTL mapping, microarray hippocampal gene expression, in vivo pharmacology with alpha3-selective modulator SB-205384, behavioral testing (Tail Suspension Test)","journal":"Mammalian genome","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo pharmacological epistasis with strain-specific genetic control (NZB lacking Gabra3 as negative control), single lab","pmids":["20512339"],"is_preprint":false},{"year":2025,"finding":"GABRA3 variants can cause either gain-of-function (GOF) or loss-of-function (LOF) effects as determined by electrophysiology. GOF variants are associated with severe treatment-resistant epilepsy and profound intellectual disability predominantly in males, while LOF variants produce milder phenotypes with behavioral issues. A GOF knock-in mouse model (Gabra3Q242L/+) showed increased seizure susceptibility, early death, and cortical hyperexcitability, demonstrating that the functional impact of a variant (not just its presence) determines dominant vs. recessive X-linked inheritance.","method":"Electrophysiology (functional variant analysis), deep phenotyping cohort of 43 individuals with 19 variants, targeted GOF knock-in mouse model (Gabra3Q242L/+) with seizure susceptibility and EEG cortical excitability measurements","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1 / Strong — electrophysiological functional classification of multiple variants combined with targeted mouse model recapitulating human phenotype, multiple orthogonal methods","pmids":["41289009"],"is_preprint":false}],"current_model":"GABRA3 encodes the alpha3 subunit of the GABAA receptor, which mediates GABA-evoked anion currents; pathogenic variants can cause gain-of-function (severe epilepsy, dominant in males) or loss-of-function (milder neurodevelopmental phenotype, recessive); in cancer contexts, unedited GABRA3 activates AKT and JNK/AP-1 signaling to promote cell migration, invasion, and MMP upregulation, while A-to-I RNA editing of GABRA3 reduces cell surface expression, stabilizes the transcript/protein, and suppresses AKT activation and invasive behavior."},"narrative":{"mechanistic_narrative":"GABRA3 encodes the alpha3 subunit of the GABAA receptor, mediating GABA-evoked anion currents that govern neuronal inhibition [PMID:29053855]. Rare missense variants distributed across the extracellular GABA-binding NH2-terminus, the M2-M3 linker, and the M4 transmembrane segment alter channel function, producing either loss-of-function or gain-of-function effects on GABA-evoked currents [PMID:29053855, PMID:41289009]. The direction of this functional impact determines the clinical outcome and X-linked inheritance pattern: gain-of-function variants cause severe treatment-resistant epilepsy and profound intellectual disability predominantly in males, recapitulated by a Gabra3 Q242L/+ knock-in mouse showing increased seizure susceptibility and cortical hyperexcitability, whereas loss-of-function variants give milder phenotypes [PMID:41289009]. At the behavioral level, positive pharmacological modulation of the alpha3 subunit modulates behavioral despair in vivo, an effect absent in mice lacking hippocampal Gabra3 [PMID:20512339]. Beyond its neuronal role, GABRA3 acts as a pro-metastatic effector in cancer, activating AKT signaling to drive cell migration and invasion [PMID:26869349] and inducing MMP-2 and MMP-9 expression through the JNK/AP-1 pathway [PMID:27081042]; A-to-I RNA editing (I343M) reduces cell surface expression while stabilizing the transcript and protein and suppressing AKT activation and the invasive phenotype [PMID:26869349, PMID:33062411]. GABRA3 expression is directly repressed by miR-92b-3p, inactivating AKT/mTOR and JNK signaling [PMID:29078789].","teleology":[{"year":2010,"claim":"Established that the GABRA3-encoded alpha3 subunit has a behaviorally relevant in vivo function, linking it causally to behavioral despair through pharmacological modulation.","evidence":"QTL mapping, hippocampal microarray, and in vivo pharmacology with the alpha3-selective modulator SB-205384 in the Tail Suspension Test, using NZB mice lacking hippocampal Gabra3 as a genetic negative control","pmids":["20512339"],"confidence":"Medium","gaps":["Does not define the circuit or downstream molecular events linking alpha3 channel activity to the behavioral phenotype","Reliance on a strain difference rather than targeted knockout"]},{"year":2016,"claim":"Revealed a non-neuronal oncogenic function for GABRA3 and showed that A-to-I RNA editing acts as a regulatory switch on its pro-metastatic activity.","evidence":"Reciprocal knockdown and overexpression cell-based migration/invasion assays, AKT pathway readouts, and cell surface expression analysis comparing edited versus unedited GABRA3 in breast cancer models","pmids":["26869349"],"confidence":"High","gaps":["Mechanism by which a GABAA channel subunit activates AKT is not defined","Does not establish how editing reduces surface expression mechanistically"]},{"year":2016,"claim":"Extended the oncogenic mechanism by connecting GABRA3 to matrix remodeling via a defined signaling pathway.","evidence":"In vitro invasion assays and in vivo mouse models in lung adenocarcinoma, measuring MMP-2/MMP-9 expression and JNK/AP-1 pathway activation after GABRA3 modulation","pmids":["27081042"],"confidence":"Medium","gaps":["Single lab; relationship between JNK/AP-1 and the AKT arm not integrated","No structural basis for pathway engagement"]},{"year":2017,"claim":"Identified an upstream regulator controlling GABRA3 levels and confirmed the downstream oncogenic pathways it governs.","evidence":"Dual-luciferase reporter assay confirming direct miR-92b-3p targeting, plus qPCR, immunoblotting, migration/invasion assays, and xenografts in pancreatic cancer cells","pmids":["29078789"],"confidence":"Medium","gaps":["Does not address whether miR-92b-3p regulation operates in neuronal contexts","Relative contribution versus RNA editing as a regulatory mode unclear"]},{"year":2017,"claim":"Provided the first direct functional reconstitution establishing loss-of-function of GABA-evoked currents as a disease pathomechanism for GABRA3-associated epilepsy and intellectual disability.","evidence":"Electrophysiology in Xenopus oocytes expressing mutant versus wild-type subunits across defined domains, with X-inactivation studies and fibroblast expression analysis","pmids":["29053855"],"confidence":"High","gaps":["Did not capture the gain-of-function variant class later identified","Does not resolve genotype-phenotype rules for X-linked inheritance"]},{"year":2020,"claim":"Clarified the molecular consequence of A-to-I editing on GABRA3, showing the I343M edit stabilizes transcript and protein and is functionally more suppressive of invasion.","evidence":"Exogenous expression of edited versus unedited GABRA3 in glioma cells with transcript/protein quantification and migration/invasion assays","pmids":["33062411"],"confidence":"Medium","gaps":["Mechanism of editing-induced stabilization not defined","Single lab and single tumor context"]},{"year":2025,"claim":"Unified the variant landscape by demonstrating that the direction of functional impact (GOF vs LOF), not variant presence, determines dominant versus recessive X-linked phenotype severity.","evidence":"Electrophysiological functional classification of 19 variants across a 43-individual cohort plus a targeted Gabra3 Q242L/+ GOF knock-in mouse with seizure susceptibility and EEG cortical excitability measurements","pmids":["41289009"],"confidence":"High","gaps":["Does not define the receptor subtype-level mechanism by which GOF currents produce hyperexcitability","Therapeutic implications of the GOF/LOF distinction untested"]},{"year":null,"claim":"How a plasma-membrane GABAA receptor subunit mechanistically couples to intracellular AKT and JNK/AP-1 signaling in cancer cells remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No defined molecular intermediary linking GABRA3 channel function to AKT activation","Whether the oncogenic and neuronal functions share a common signaling mechanism is unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[2,6]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,4]}],"pathway":[{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[2,6]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,3]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,6]}],"complexes":["GABAA receptor"],"partners":[],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P34903","full_name":"Gamma-aminobutyric acid receptor subunit alpha-3","aliases":["GABA(A) receptor subunit alpha-3","GABAAR subunit alpha-3"],"length_aa":492,"mass_kda":55.2,"function":"Alpha subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (PubMed:16412217, PubMed:29053855). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (By similarity). When activated by GABA, GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient (PubMed:16412217, PubMed:29053855). Chloride influx into the postsynaptic neuron following GABAAR opening decreases the neuron ability to generate a new action potential, thereby reducing nerve transmission (PubMed:16412217, PubMed:29053855)","subcellular_location":"Postsynaptic cell membrane; Cell membrane","url":"https://www.uniprot.org/uniprotkb/P34903/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GABRA3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GABRA3","total_profiled":1310},"omim":[{"mim_id":"312750","title":"RETT SYNDROME; RTT","url":"https://www.omim.org/entry/312750"},{"mim_id":"305660","title":"GAMMA-AMINOBUTYRIC ACID RECEPTOR, ALPHA-3; GABRA3","url":"https://www.omim.org/entry/305660"},{"mim_id":"305000","title":"DYSKERATOSIS CONGENITA, X-LINKED; DKCX","url":"https://www.omim.org/entry/305000"},{"mim_id":"301870","title":"BIGLYCAN; BGN","url":"https://www.omim.org/entry/301870"},{"mim_id":"301091","title":"EPILEPSY, X-LINKED 2, WITH OR WITHOUT IMPAIRED INTELLECTUAL DEVELOPMENT AND DYSMORPHIC FEATURES; EPILX2","url":"https://www.omim.org/entry/301091"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":16.4},{"tissue":"choroid plexus","ntpm":32.1},{"tissue":"retina","ntpm":8.3}],"url":"https://www.proteinatlas.org/search/GABRA3"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P34903","domains":[{"cath_id":"2.70.170.10","chopping":"63-273","consensus_level":"high","plddt":93.2736,"start":63,"end":273},{"cath_id":"1.20.58.390","chopping":"276-366_452-489","consensus_level":"high","plddt":90.3917,"start":276,"end":489}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P34903","model_url":"https://alphafold.ebi.ac.uk/files/AF-P34903-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P34903-F1-predicted_aligned_error_v6.png","plddt_mean":76.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GABRA3","jax_strain_url":"https://www.jax.org/strain/search?query=GABRA3"},"sequence":{"accession":"P34903","fasta_url":"https://rest.uniprot.org/uniprotkb/P34903.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P34903/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P34903"}},"corpus_meta":[{"pmid":"26869349","id":"PMC_26869349","title":"The mRNA-edited form of GABRA3 suppresses GABRA3-mediated Akt activation and breast cancer metastasis.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26869349","citation_count":170,"is_preprint":false},{"pmid":"29078789","id":"PMC_29078789","title":"miR-92b-3p acts as a tumor suppressor by targeting Gabra3 in pancreatic cancer.","date":"2017","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29078789","citation_count":98,"is_preprint":false},{"pmid":"11840313","id":"PMC_11840313","title":"Excess of allele1 for alpha3 subunit GABA receptor gene (GABRA3) in bipolar patients: a multicentric association study.","date":"2002","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/11840313","citation_count":45,"is_preprint":false},{"pmid":"29053855","id":"PMC_29053855","title":"Rare GABRA3 variants are associated with epileptic seizures, encephalopathy and dysmorphic features.","date":"2017","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/29053855","citation_count":43,"is_preprint":false},{"pmid":"1684949","id":"PMC_1684949","title":"Physical mapping of the loci Gabra3, DXPas8, CamL1, and Rsvp in a region of the mouse X chromosome homologous to human Xq28.","date":"1991","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1684949","citation_count":27,"is_preprint":false},{"pmid":"27081042","id":"PMC_27081042","title":"GABRA3 promotes lymphatic metastasis in lung adenocarcinoma by mediating upregulation of matrix metalloproteinases.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27081042","citation_count":19,"is_preprint":false},{"pmid":"8088815","id":"PMC_8088815","title":"A 2.3-Mb yeast artificial chromosome contig spanning from Gabra3 to G6pd on the mouse X chromosome.","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8088815","citation_count":17,"is_preprint":false},{"pmid":"33062411","id":"PMC_33062411","title":"Global RNA editome landscape discovers reduced RNA editing in glioma: loss of editing of gamma-amino butyric acid receptor alpha subunit 3 (GABRA3) favors glioma migration and invasion.","date":"2020","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/33062411","citation_count":16,"is_preprint":false},{"pmid":"20512339","id":"PMC_20512339","title":"Quantitative trait locus analysis identifies Gabra3 as a regulator of behavioral despair in mice.","date":"2010","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/20512339","citation_count":13,"is_preprint":false},{"pmid":"8546157","id":"PMC_8546157","title":"Lack of association between manic-depressive illness and a highly polymorphic marker from GABRA3 gene.","date":"1995","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8546157","citation_count":12,"is_preprint":false},{"pmid":"17970773","id":"PMC_17970773","title":"Association of genetic variants in GABRA3 gene and thyrotoxic hypokalaemic periodic paralysis in Thai population.","date":"2007","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17970773","citation_count":11,"is_preprint":false},{"pmid":"31593956","id":"PMC_31593956","title":"Epigenetic Coactivation of MAGEA6 and CT-GABRA3 Defines Orientation of a Segmental Duplication in the Human X Chromosome.","date":"2019","source":"Cytogenetic and genome research","url":"https://pubmed.ncbi.nlm.nih.gov/31593956","citation_count":10,"is_preprint":false},{"pmid":"11602034","id":"PMC_11602034","title":"Lack of association between GABRA3 and unipolar affective disorder: a multicentre study.","date":"2001","source":"The international journal of neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11602034","citation_count":10,"is_preprint":false},{"pmid":"14751442","id":"PMC_14751442","title":"Lack of association between polymorphic variations in the alpha 3 subunit GABA receptor gene (GABRA3) and suicide attempts.","date":"2004","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/14751442","citation_count":8,"is_preprint":false},{"pmid":"26676335","id":"PMC_26676335","title":"Thyrotoxic Periodic Paralysis and Polymorphisms of the ADRB2, AR, and GABRA3 Genes in Men with Graves Disease.","date":"2016","source":"Endocrinology and metabolism (Seoul, Korea)","url":"https://pubmed.ncbi.nlm.nih.gov/26676335","citation_count":4,"is_preprint":false},{"pmid":"41289009","id":"PMC_41289009","title":"Functional consequence of pathogenic GABRA3 variants determines whether X-linked inheritance is dominant or recessive.","date":"2025","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/41289009","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":9430,"output_tokens":1864,"usd":0.028125,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8766,"output_tokens":2768,"usd":0.056515,"stage2_stop_reason":"end_turn"},"total_usd":0.08464,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2016,\n      \"finding\": \"GABRA3 activates the AKT pathway to promote breast cancer cell migration, invasion, and metastasis. A-to-I RNA-edited GABRA3 has reduced cell surface expression and suppresses AKT activation required for cell migration and invasion, thereby suppressing metastasis.\",\n      \"method\": \"Loss-of-function and gain-of-function cell-based assays (migration, invasion), AKT pathway activation assays, cell surface expression analysis of edited vs. unedited GABRA3\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal functional assays (KD and OE), AKT pathway readout, cell surface localization, replicated across multiple cancer models in single rigorous study\",\n      \"pmids\": [\"26869349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"miR-92b-3p directly targets GABRA3 (confirmed by dual-luciferase reporter assay), and miR-92b-3p overexpression suppresses GABRA3 expression, leading to inactivation of AKT/mTOR and JNK oncogenic pathways in pancreatic cancer cells.\",\n      \"method\": \"Dual-luciferase reporter assay, qPCR, immunoblotting, in vitro migration/invasion assays, xenograft mouse models\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase reporter validates direct targeting, pathway readouts, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"29078789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Rare missense variants in the extracellular GABA-binding NH2-terminus, M2-M3 linker, and M4 transmembrane segment of GABRA3 cause a variable but significant reduction of GABA-evoked anion currents compared to wild-type, indicating loss-of-function as the pathomechanism for associated epilepsy and intellectual disability.\",\n      \"method\": \"Functional electrophysiology in Xenopus laevis oocytes expressing mutant vs. wild-type GABRA3; X-chromosome inactivation studies; fibroblast expression analysis for microduplication variant\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct electrophysiological reconstitution in Xenopus oocytes for multiple variants with defined domain localizations, multiple families studied\",\n      \"pmids\": [\"29053855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GABRA3 induces MMP-2 and MMP-9 expression through activation of the JNK/AP-1 signaling pathway, enhancing lymphatic metastasis in lung adenocarcinoma both in vitro and in vivo.\",\n      \"method\": \"In vitro invasion assays, in vivo mouse models, pathway activation analysis (JNK/AP-1), MMP expression measurement after GABRA3 modulation\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo functional assays with defined pathway readout, single lab\",\n      \"pmids\": [\"27081042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Edited GABRA3 (A-to-I; I343M) has higher transcript and protein stability compared to unedited GABRA3 in glioma cells. Exogenously expressed edited GABRA3 inhibits migration and invasion of glioma cells more efficiently than unedited GABRA3, demonstrating that RNA editing stabilizes GABRA3 protein and suppresses the invasive phenotype.\",\n      \"method\": \"Exogenous expression of edited vs. unedited GABRA3 in glioma cells, transcript and protein level quantification, migration and invasion assays\",\n      \"journal\": \"PeerJ\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct comparison of edited vs. unedited protein with functional migration/invasion readout, single lab\",\n      \"pmids\": [\"33062411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"GABRA3 regulates behavioral despair (immobility in Tail Suspension Test) in vivo; pharmacological positive modulation of the GABRA3-encoded alpha3 subunit with SB-205384 significantly reduced TST immobility in wild-type mice but had no effect in NZB mice lacking hippocampal Gabra3 expression.\",\n      \"method\": \"QTL mapping, microarray hippocampal gene expression, in vivo pharmacology with alpha3-selective modulator SB-205384, behavioral testing (Tail Suspension Test)\",\n      \"journal\": \"Mammalian genome\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo pharmacological epistasis with strain-specific genetic control (NZB lacking Gabra3 as negative control), single lab\",\n      \"pmids\": [\"20512339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"GABRA3 variants can cause either gain-of-function (GOF) or loss-of-function (LOF) effects as determined by electrophysiology. GOF variants are associated with severe treatment-resistant epilepsy and profound intellectual disability predominantly in males, while LOF variants produce milder phenotypes with behavioral issues. A GOF knock-in mouse model (Gabra3Q242L/+) showed increased seizure susceptibility, early death, and cortical hyperexcitability, demonstrating that the functional impact of a variant (not just its presence) determines dominant vs. recessive X-linked inheritance.\",\n      \"method\": \"Electrophysiology (functional variant analysis), deep phenotyping cohort of 43 individuals with 19 variants, targeted GOF knock-in mouse model (Gabra3Q242L/+) with seizure susceptibility and EEG cortical excitability measurements\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — electrophysiological functional classification of multiple variants combined with targeted mouse model recapitulating human phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"41289009\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GABRA3 encodes the alpha3 subunit of the GABAA receptor, which mediates GABA-evoked anion currents; pathogenic variants can cause gain-of-function (severe epilepsy, dominant in males) or loss-of-function (milder neurodevelopmental phenotype, recessive); in cancer contexts, unedited GABRA3 activates AKT and JNK/AP-1 signaling to promote cell migration, invasion, and MMP upregulation, while A-to-I RNA editing of GABRA3 reduces cell surface expression, stabilizes the transcript/protein, and suppresses AKT activation and invasive behavior.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GABRA3 encodes the alpha3 subunit of the GABAA receptor, mediating GABA-evoked anion currents that govern neuronal inhibition [#2]. Rare missense variants distributed across the extracellular GABA-binding NH2-terminus, the M2-M3 linker, and the M4 transmembrane segment alter channel function, producing either loss-of-function or gain-of-function effects on GABA-evoked currents [#2, #6]. The direction of this functional impact determines the clinical outcome and X-linked inheritance pattern: gain-of-function variants cause severe treatment-resistant epilepsy and profound intellectual disability predominantly in males, recapitulated by a Gabra3 Q242L/+ knock-in mouse showing increased seizure susceptibility and cortical hyperexcitability, whereas loss-of-function variants give milder phenotypes [#6]. At the behavioral level, positive pharmacological modulation of the alpha3 subunit modulates behavioral despair in vivo, an effect absent in mice lacking hippocampal Gabra3 [#5]. Beyond its neuronal role, GABRA3 acts as a pro-metastatic effector in cancer, activating AKT signaling to drive cell migration and invasion [#0] and inducing MMP-2 and MMP-9 expression through the JNK/AP-1 pathway [#3]; A-to-I RNA editing (I343M) reduces cell surface expression while stabilizing the transcript and protein and suppressing AKT activation and the invasive phenotype [#0, #4]. GABRA3 expression is directly repressed by miR-92b-3p, inactivating AKT/mTOR and JNK signaling [#1].\",\n  \"teleology\": [\n    {\n      \"year\": 2010,\n      \"claim\": \"Established that the GABRA3-encoded alpha3 subunit has a behaviorally relevant in vivo function, linking it causally to behavioral despair through pharmacological modulation.\",\n      \"evidence\": \"QTL mapping, hippocampal microarray, and in vivo pharmacology with the alpha3-selective modulator SB-205384 in the Tail Suspension Test, using NZB mice lacking hippocampal Gabra3 as a genetic negative control\",\n      \"pmids\": [\"20512339\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not define the circuit or downstream molecular events linking alpha3 channel activity to the behavioral phenotype\", \"Reliance on a strain difference rather than targeted knockout\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealed a non-neuronal oncogenic function for GABRA3 and showed that A-to-I RNA editing acts as a regulatory switch on its pro-metastatic activity.\",\n      \"evidence\": \"Reciprocal knockdown and overexpression cell-based migration/invasion assays, AKT pathway readouts, and cell surface expression analysis comparing edited versus unedited GABRA3 in breast cancer models\",\n      \"pmids\": [\"26869349\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which a GABAA channel subunit activates AKT is not defined\", \"Does not establish how editing reduces surface expression mechanistically\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Extended the oncogenic mechanism by connecting GABRA3 to matrix remodeling via a defined signaling pathway.\",\n      \"evidence\": \"In vitro invasion assays and in vivo mouse models in lung adenocarcinoma, measuring MMP-2/MMP-9 expression and JNK/AP-1 pathway activation after GABRA3 modulation\",\n      \"pmids\": [\"27081042\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; relationship between JNK/AP-1 and the AKT arm not integrated\", \"No structural basis for pathway engagement\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified an upstream regulator controlling GABRA3 levels and confirmed the downstream oncogenic pathways it governs.\",\n      \"evidence\": \"Dual-luciferase reporter assay confirming direct miR-92b-3p targeting, plus qPCR, immunoblotting, migration/invasion assays, and xenografts in pancreatic cancer cells\",\n      \"pmids\": [\"29078789\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not address whether miR-92b-3p regulation operates in neuronal contexts\", \"Relative contribution versus RNA editing as a regulatory mode unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Provided the first direct functional reconstitution establishing loss-of-function of GABA-evoked currents as a disease pathomechanism for GABRA3-associated epilepsy and intellectual disability.\",\n      \"evidence\": \"Electrophysiology in Xenopus oocytes expressing mutant versus wild-type subunits across defined domains, with X-inactivation studies and fibroblast expression analysis\",\n      \"pmids\": [\"29053855\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not capture the gain-of-function variant class later identified\", \"Does not resolve genotype-phenotype rules for X-linked inheritance\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Clarified the molecular consequence of A-to-I editing on GABRA3, showing the I343M edit stabilizes transcript and protein and is functionally more suppressive of invasion.\",\n      \"evidence\": \"Exogenous expression of edited versus unedited GABRA3 in glioma cells with transcript/protein quantification and migration/invasion assays\",\n      \"pmids\": [\"33062411\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of editing-induced stabilization not defined\", \"Single lab and single tumor context\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Unified the variant landscape by demonstrating that the direction of functional impact (GOF vs LOF), not variant presence, determines dominant versus recessive X-linked phenotype severity.\",\n      \"evidence\": \"Electrophysiological functional classification of 19 variants across a 43-individual cohort plus a targeted Gabra3 Q242L/+ GOF knock-in mouse with seizure susceptibility and EEG cortical excitability measurements\",\n      \"pmids\": [\"41289009\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not define the receptor subtype-level mechanism by which GOF currents produce hyperexcitability\", \"Therapeutic implications of the GOF/LOF distinction untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a plasma-membrane GABAA receptor subunit mechanistically couples to intracellular AKT and JNK/AP-1 signaling in cancer cells remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No defined molecular intermediary linking GABRA3 channel function to AKT activation\", \"Whether the oncogenic and neuronal functions share a common signaling mechanism is unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [2, 6]},\n      {\"term_id\": \"GO:0005230\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [2, 6]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 3]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 6]}\n    ],\n    \"complexes\": [\"GABAA receptor\"],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":6,"faith_pct":83.33333333333333}}